Medical device companies find an ideal home in the UM BioPark

Published on :

In 2003, a group of University of Maryland officials approached then-mayor Martin O’Malley with a development plan for vacant land along West Baltimore Street, adjacent to University of Maryland, Baltimore’s campus. Today, this ambitious project, the University of Maryland BioPark, boasts nearly three dozen life science companies, ranging from leading global firms to mature companies to early-stage ventures.
In recent years, the BioPark has attracted a cluster of early-stage medical device companies. For these young companies, the BioPark offers something even more important than a corporate headquarters: a location on UMB’s campus and in the heart of Maryland’s biomed ecosystem.
“The real magnet to coming to our research park is the University of Maryland, Baltimore,” said UM BioPark Executive Director Jane Shaab. “As a leading academic medical center, the quality and scope of research going on here is what companies want to access.”

AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in Q1, 2022

Published on :

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a US and China-based biotechnology company focused on early cancer screening and detection, announced today that on December 30, 2021, the Company’s Class III medical device for lung cancer auxiliary diagnosis has completed and passed stringent and rigorous registration tests at the testing laboratory designated by the National Medical Products Administration (NMPA), China’s regulatory agent for medical products.  China’s extensive Class III medical device registration tests included medical device performance tests related to accuracy, precision, stability, linearity, accuracy and repeatability in sample addition, cross-contamination, electromagnetic compatibility (EMC), and reliability and performance under various environmental conditions.  Completion of the NMPA registration tests is a significant milestone toward obtaining a Class III medical device registration certificate. Following completion of the registration test, the remaining major step prior to final approval of a registration certificate will be clinical trials which will begin in the first quarter of 2022 with two qualified clinical trial medical institutions.

FDA Grants Theradaptive Breakthrough Medical Device Designation

Theradaptive Logo
Published on :

Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation to its Osteo-Adapt SP Spinal Fusion implant indicated for transforaminal lumbar interbody spinal fusion to treat degenerative disc disease, spondylolisthesis, or retrolisthesis.

Medcura raises $7.4 Million to Expand FDA-Approved Line of Hemostatic and Wound Treatment Products

Published on :

Medcura, Inc., a commercial-stage medical device company, today announced it has raised $7.4 million in private equity to support its growing product line and development of its lead surgical candidate for clinical evaluation. The financing includes the sale of Series A Preferred stock as well as common stock based, in part, from certain investors benefitting from a Maryland Investment Incentive Program.

Changing Careers – Leaving The Medical Device Field To Work In A Biotech Startup

Published on :

Why would any sane person leave the bleeding-edge medical device space after 25 years for a biotech startup? The medical device world allows you to represent products where you see the benefits to patients immediately. We had the privilege of wearing scrubs and offering our expertise in the procedure room. I was fortunate to work with some of the greatest cardiovascular minds in the world. Having built that trust and credibility is something I’ll never forget. So why move along?

“Make Your Medical Device Pitch for Kids!”Competition Accepting Applications

Published on :

Critical Need For Electrophysiology Devices To Treat Pediatric Heart Patients WASHINGTON – (March 23, 2021) – Congenital heart disease (CHD) affects six out of 1,000 babies born in the U.S. [….]

‘Best Kept Secret’ MDC Provides Path for Medical Device Innovations

Published on :

In the heart of pharmaceutical and medical innovation lies an undiscovered treasure that provides a pathway for med-tech innovation, the Maryland Development Council (MDC). The council is a MedTech Startup Studio that works with inventors to develop their ideas into working prototypes and marketable products.

5 Questions with Thomas “Tommy” Miller, Esq., Senior Counsel and Life Science Lead, Nixon Gwilt Law

Published on :

Thomas (“Tommy”) Miller, Esq., is Senior Counsel and Life Science Lead at Nixon Gwilt Law and is licensed in Virginia, Washington, D.C., and Maryland. Tommy has supported innovation and served clients in the healthcare and life science industries for over 10 years.